Paris-based MSInsight, a startup innovating precision medicine solutions in oncology, has closed a €1.6 million Seed funding round to accelerate the development and regulatory approval of MSIcare, its AI-powered diagnostic software designed to enhance the accuracy of detecting microsatellite instability (MSI) cancers.
The investment was led by Calyseed, with participation from Plateau de Saclay Business Angels, Yes Invest, Capital Cell, and banking support from bpifrance.
“This fundraising marks a key milestone for MSInsight. It gives us the means to accelerate the deployment of our technology and strengthen our clinical partnerships. We have already proven that our approach outperforms current methods in several types of cancer. Thanks to this funding, we are preparing the CE-IVD certification procedures for MSIcare.
“The company’s ambition is to position its MSIcare solution as the future gold standard for assessing microsatellite instability and the first regulatory – valida ted bioinformatics solution,” said Arnaud Cutivet, PhD, president and Co-founder of MSInsight.
Founded in 2022, MSInsight is focused on transforming cancer diagnostics by leveraging next-generation sequencing (NGS) and advanced bioinformatics. Their approach is rooted in two decades of academic research from Inserm, Assistance Publique des Hôpitaux de Paris, and Sorbonne University, spearheaded by Prof. Alex Duval, the company’s Scientific Director.
The startup’s core innovation, MSIcare, is designed to overcome the limitations of existing diagnostic methods, which can be inaccurate in up to 30% of cases (as per MSIcare). By improving MSI biomarker detection, the technology ensures that more cancer patients receive appropriate treatments, particularly immunotherapy, which has shown significant survival benefits.
The company’s technology addresses a critical gap in cancer diagnostics. MSI cancers represent nearly one million new cases annually worldwide, spanning various organ types, particularly digestive and gynaecological cancers.
The MSI biomarker plays a crucial role in determining the suitability of immunotherapy, making accurate, large-scale detection essential for effective treatment pathways. Despite existing diagnostic techniques, inaccuracies remain a challenge, leading to misdiagnoses, inappropriate treatments, and unnecessary healthcare costs.
In addition, the company aims to extend its diagnostic solutions to pediatric oncology and hereditary cancer screening, including applications for Lynch syndrome, one of the most common genetic predispositions to cancer.
“MSIcare has the potential to become a standard in oncology diagnostics, significantly improving the therapeutic orientation and care pathway. We strongly believe in this solution, which is part of an evolving trend of using NGS sequencing tests to diagnose and use MSI biomarkers in oncology. The bioinformatics software developed can be easily integrated into laboratory practices.
“MSInsight’s innovation has already demonstrated its performance and reliability in retrospective studies. The startup benefits from intellectual rights, an expert team, and a network of quality partners that should make it possible to reach the key milestones for the next round of funding,” said Elodie Panier, Managing Director of Calyseed.
“Capital Cell is thrilled to have directed significant funding from more than 170 investors to MSInsight, a company that demonstrates immense potential in the field of cancer care,” said Daniel Oliver, Director of Capital Cell.
With its latest funding round, MSInsight is moving closer to its mission of making high-precision MSI diagnostics widely accessible, preventing misdiagnoses, and ensuring optimal treatment pathways for cancer patients.
Read the orginal article: https://www.eu-startups.com/2025/03/msinsight-secures-e1-6-million-to-redefine-msi-cancer-diagnosis/
